SCHEMBL10063578

SCHEMBL10063578

Cn1nc(C=O)c2cccnc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
FEN1 P39748 1/20 0.41
KMT2A Q03164 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
HSP90AA1 P07900 1/20 0.39
IDO1 P14902 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SSTR4 P31391 1/20 0.38
NAMPT P43490 1/20 0.38
ELANE P08246 3/20 0.37
PDE4A P27815 2/20 0.37
PDE4B Q07343 2/20 0.37
PDE4C Q08493 2/20 0.37
PDE4D Q08499 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29935946 1.00 KDM5A (0.41) KDM5AKDM4CKDM5BFEN1KMT2A
SCHEMBL5262178 0.79 KMT2A (0.39) FEN1KMT2AL3MBTL1KDM4EMEN1
Formamide SCHEMBL28600746 0.77 L3MBTL1 (0.47) KDM5AKDM4CKDM5BFEN1L3MBTL1
SCHEMBL1747623 0.74 GSK3B (0.54) KDM5AKDM4CKDM5BFEN1KMT2A
SCHEMBL626956 0.74 L3MBTL1 (0.54) KDM5AKDM4CKDM5BFEN1L3MBTL1
SCHEMBL26982413 0.74 NAMPT (0.42) KDM5AKDM4CKDM5BFEN1KMT2A
SCHEMBL20551427 0.73 KDM5A (0.44) KDM5AKDM4CKDM5BFEN1L3MBTL1
SCHEMBL29561158 0.73 ALDH1A1 (0.46) KDM4CL3MBTL1KDM4EHSP90AA1IDO1
SCHEMBL465585 0.73 ALDH1A1 (0.46) KDM4CL3MBTL1KDM4EHSP90AA1IDO1
SCHEMBL31298603 0.73 KDM5A (0.44) KDM5AKDM4CKDM5BFEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11597728-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-03-07 US claimed
EP-3856179-A1 MONOACYLGLYCEROL LIPASE MODULATORS Janssen Pharmaceutica N.V. (BE) 2021-08-04 EP claimed
WO-2020065614-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 WO claimed
US-20200102311-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 US claimed
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 EP disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
US-11993601-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV 2024-05-28 US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-11597728-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-03-07 US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 US disclosed
US-20130184289-A1 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES CHEMOCENTRYX INC. (US) 2013-07-18 US disclosed
US-8481545-B2 3-(imidazolyl)-pyrazolo[3,4-b] pyridines CHEMOCENTRYX, INC. (US) 2013-07-09 US disclosed
US-20120010214-A1 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES CHEMOCENTRYX, INC. (US) 2012-01-12 US disclosed
US-7960388-B2 3-(imidazolyl)-pyrazolo[3,4-b]pyridines CHEMOCENTRYX, INC. (US) 2011-06-14 US disclosed
US-20100173911-A1 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES CHEMOCENTRYX, INC. (US) 2010-07-08 US disclosed
US-20100113472-A1 COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS CHEMOCENTRYX, INC. (US) 2010-05-06 US disclosed
US-7629344-B2 3-(imidazolyl)-pyrazolo[3,4-b]pyridines CHEMOCENTRYX, INC. (US) 2009-12-08 US disclosed
US-20080300257-A1 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES CHEMOCENTRYX, INC. (US) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP KDM5A 3324/4885KDM4C 3010/4885KDM5B 3350/4885
US-20130184289-A1 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES CCR1, CCR3, CCR4 KDM5A 4169/4885KDM4C 3700/4885KDM5B 3701/4885
US-20230242531-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP KDM5A 3404/4885KDM4C 3292/4885KDM5B 3249/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH KDM5A 4314/4885KDM4C 3490/4885KDM5B 4467/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP KDM5A 3324/4885KDM4C 3010/4885KDM5B 3350/4885
US-20080300257-A1 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES CCR1, CCR3, CCR4 KDM5A 4169/4885KDM4C 3700/4885KDM5B 3701/4885
US-20100113472-A1 COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS SOST, VDR, PTH1R KDM5A 838/4885KDM4C 309/4885KDM5B 299/4885
US-11993601-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP KDM5A 3404/4885KDM4C 3292/4885KDM5B 3249/4885
US-20120010214-A1 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES CCR1, CCR3, CCR4 KDM5A 4169/4885KDM4C 3700/4885KDM5B 3701/4885
US-20200102311-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP KDM5A 3404/4885KDM4C 3292/4885KDM5B 3249/4885
US-11597728-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP KDM5A 3404/4885KDM4C 3292/4885KDM5B 3249/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP KDM5A 3324/4885KDM4C 3010/4885KDM5B 3350/4885
US-20100173911-A1 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES CCR1, CCR3, CCR4 KDM5A 4169/4885KDM4C 3700/4885KDM5B 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.